Sanome has secured Class IIb CE certification and MHRA approval for MEMORI, an AI-enabled warning system for the early prediction/prevention of healthcare‑associated infections (HAIs).
Everest Medicines has announced that the supplemental application for the production expansion of NEFECON has been officially approved by China’s National Medical Products Administration (NMPA).
An investment of $1 billion to increase access to innovative antibiotics and high-quality treatment of antimicrobial resistance (AMR), could boost the European Union’s (EU) economy by $88 billion a year, by the year 2050.
Qureight, a techbio company accelerating drug development using its proprietary deep-learning image biomarkers and clinical data analytics platform, has announced the first results from a collaboration with Insilico Medicine.
The biotech company, Pila Pharma, is raising 20 million Swedish kronor in an almost fully covered capital raise, which includes a stock option for future use.
Biocon Biologics, a fully integrated global biosimilars company and subsidiary of Biocon, has announced that the Medicines and Healthcare products Regulatory Agency (MHRA) granted marketing authorisations in the UK for Vevzuo and Evfraxy.
Dr Audrey Dubourg, product manager, and Ayisha I. A. Malik, content marketing manager CN Bio, discuss how to effectively adopt and leverage Organ-on-a-chip to drive more effective drug development.
Oxford-based SynaptixBio, which is developing a therapy for a rare, deadly, and currently incurable rare disease (H-ABC), says it has identified the drug it will take forward into clinical trials.
Italfarmaco has announced that the European Commission (EC) has granted conditional marketing authorisation for Duvyzat (givinostat), a novel histone deacetylase (HDAC) inhibitor.
pharma& has announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted a variation to the Marketing Authorisation for Pegasys (peginterferon alfa-2a).
Biocon Biologics, a fully integrated global biosimilars company and subsidiary of Biocon, has announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation in the United Kingdom (UK) for YESINTEK.
